Debiopharm
Holding Companies & Conglomerates · Switzerland · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Chemin Messidor 5-7, Lausanne, Vaud, 100...Phone Number
+41 213312930Website
www.debiopharm.comRevenue
$141.8 MillionIndustry
ZI Rank: 13
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
13
3
15
14
13
About Debiopharm
Debiopharm Investment, previously known as Debiomanagement, serves as the investment division of Debiopharm Group. Its primary goals include safeguarding Debiopharm Group's capital and generating consistent financial returns for its subsidiaries. Debiopharm Investment encompasses departments focused on finance, real estate, and private equity.Explore more
Debiopharm Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Debiopharm your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Debiopharm is spiking on competitors!
Funding: Get notified immidiatlly once Debiopharm has new funding data
Product Launch: Get notified when Debiopharm launches new products
Earning: See what the market has to say on Debiopharm recently announced quarterly report
Check if Debiopharm has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Debiopharm
Website visits: Recent activity has been detected on your website
Click to see if Debiopharm had a recent Job posting/layoffs
Debiopharm, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Debiopharm
Find 3 more new buyers
Company Profile Activity
Activity Insights
Debiopharm is experiencing very low activity levels compared to other companies in the Holding Companies & Conglomerates sector.
What does this means?
Debiopharm is drawing exceptional interest within the Holding Companies & Conglomerates industry, suggesting notable developments or strong market momentum, learn more about Debiopharm.
Debiopharm financials insights
Gather financial insights about Debiopharm, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Grant
$1M
2022
Unspecified
$6M
Debiopharm Tech Stack
A closer look at the technologies used by Debiopharm
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Event
Product Marketing, Events, Sales, Digital Technology, Software, Field /Outside Sales, Field Marketing, Healthcare Operations, Healthcare Technology, Operations, Patient Experience, Telemedicine
Open Position
Open Position
Open Position
Debiopharm News & Media
ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal Cell Carcinoma (ccRCC)
Garching / Munich, Germany, and Lausanne, Switzerland - June 23, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and Debiopharm, a Swiss-based, global biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced that the first patient was imaged in a new study arm of a five-part, Phase 1/2 clinical trial (formerly GaLuCi™) (NCT05706129) evaluating the theranostic pair ITM-94/ITM-91Debiopharm and Alkyon Therapeutics Announce Research Collaboration to Advance the Next Generation of Radioligand Therapies
MARTIGNY, Switzerland & LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned Swiss biopharmaceutical company committed to establishing tomorrow’s standard of care to cure cancer and infectious diseases and Alkyon Therapeutics, Inc., a biotechnology company pioneering precision-targeted therapies, today announced the signing of a co-research agreement to evaluate the feasibility of developing targeted radioligand therapies (RLTs) using DebiopharmDebiopharm Ignites Oncology Innovation With Clinical and Translational Data on Debio 0123 at the 2025 ASCO Annual Meeting in Chicago
LAUSANNE, Switzerland--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today unveiled its upcoming contributions to the 2025 Annual American Society of Clinical Oncology (ASCO) Meeting in Chicago, Illinois. The contributions feature three clinical poster presentations and one translational research abstract publication, highlighting Debio 0123’s poteDebiopharm and Oncodesign Services Launch Strategic Collaboration to Propel Radiopharmaceuticals in Preclinical Research
MARTIGNY, Switzerland & DIJON, France--(BUSINESS WIRE)--Debiopharm Research & Manufacturing S.A. (Debiopharm, www.debiopharm.com), a Swiss-based global biopharmaceutical company aiming to cure cancer and infectious diseases, and Oncodesign Services (www.oncodesign-services.com), a leading CRO specialized in drug discovery and preclinical services, announce the execution of a license agreement for the use of the AbYlink™ technology for preclinical services. AbYlink™ is a regio-selective bioc
Read more news
Top Holding Companies & Conglomerates Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Debiopharm
Sign Up For FreeTo access detailed company insights
Debiopharm Investment, previously known as Debiomanagement, serves as the investment division of Debiopharm Group. Its primary goals include safeguarding Debiopharm Group's capital and generating consistent financial returns for its subsidiaries. Debiopharm Investment encompasses departments focused on finance, real estate, and private equity.... Read More
